Invivyd (IVVD) Other Accumulated Expenses (2022 - 2026)
Invivyd's (IVVD) quarterly Other Accumulated Expenses came in at $71000.0 in Q2 2026, up 173.08% on a YoY basis from $26000.0 in Q2 2025, and up 36.54% quarter-over-quarter from $52000.0 in Q4 2025.
Analysis
Invivyd (IVVD) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Other Accumulated Expenses for 5 consecutive years, with $71000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Accumulated Expenses rose 173.08% year-over-year to $71000.0; the trailing twelve-month figure through Jun 2026 stood at $71000.0 (up 173.08% YoY), and the FY2025 full-year result was $52000.0, up 92.59% from the prior year.
- Other Accumulated Expenses grew to $71000.0 in Q2 2026 per IVVD's latest filing, from $52000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $71000.0 in Q2 2026 and bottomed at $20000.0 in Q3 2024.
- Historically, Other Accumulated Expenses has averaged $39750.0 across 5 years, with a median of $36500.0 in 2023.
- The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses tumbled 49.06% in 2023, then jumped 173.08% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $44000.0 in 2022, then decreased by 20.45% to $35000.0 in 2023, then declined by 22.86% to $27000.0 in 2024, then jumped by 92.59% to $52000.0 in 2025, then jumped by 36.54% to $71000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $71000.0, $52000.0, and $32000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | 58,000.00 |
| Dec 31, 2022 | 44,000.00 |
| Sep 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 58,000.00 |